Nice says life-prolonging kidney cancer drugs too costly for NHS

Nice, the body which approves drugs for use in the NHS, says they prolong the lives of people dying from advanced kidney cancer, but do not offer value for money and should not be available on the NHS in England and Wales.

The government's advisory body does say, however, that they should continue to be used by those already receiving treatment.

It has reached this new funding conclusion because of the cost of the drugs; up to £35,000 a year per patient, and the effect on NHS resources.

Cancer charities say it should think again.

Click here to go to the Cancer Research UK site where you can have your say on the Nice funding decision.

Share this article

Send this article to a friend »

• Del.icio.us
• Digg
• Reddit
• Facebook
• StumbleUpon

What are these?